Drug manufacturer Biofarm (stock symbol: BIO) ended the first nine months of 2025 with a turnover of RON263.2 million, up 14% against the year-earlier period, and EBITDA climbed 16% to RON109 million.
Shareholders of pharmaceutical producer Biofarm (BIO.RO) approved at their general meeting on April 28 the distribution of the company's net profit of RON74.4 million for 2024, as per a report sent to the Bucharest Stock Exchange.